Clinical Trials
36 trialsNCT04172675 2026-02-24
A Study of Erdafitinib Versus Investigator Choice of Intravesical Chemotherapy in Participants Who Received Bacillus Calmette-Guérin (BCG) and Recurred With High Risk Non-Muscle-Invasive Bladder Cancer (NMIBC)
Janssen Research & Development, LLC
Phase 2 Completed
NCT05375903 2026-01-14
A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma Ltd.
Phase 1 Completed
NCT03081858 2025-06-27
Proliposomal Intravesical Paclitaxel for Treatment of Low-Grade, Stage Ta, Non Muscle Invasive Bladder Cancer
Lipac Oncology LLC
Phase 1/2 Completed
NCT05945108 2025-04-11
Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER
AstraZeneca
Completed
NCT05085977 2025-01-27
ADVANCED-1
Protara Therapeutics
Phase 1 Completed
NCT05085990 2025-01-27
ADVANCED-1
Protara Therapeutics
Phase 1 Completed
NCT04387461 2024-09-25
CORE-001
CG Oncology, Inc.
Phase 2 Completed
NCT05136898 2024-09-19
Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle Invasive Bladder Cancer (NMIBC)
UroGen Pharma Ltd.
Phase 3 Completed
NCT02773849 2024-07-29
ADSTILADRIN (=INSTILADRIN) in Patients With High-Grade, Bacillus Calmette-Guerin (BCG) Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC)
Ferring Pharmaceuticals
Phase 3 Completed
NCT06020807 2023-09-07
Analytical Specificity of Bladder EpiCheck Test in Healthy Population and Urology Patients Without Prior History or Evidence of Bladder Cancer
Nucleix Ltd.
Completed
NCT03636256 2023-08-14
Evaluation of NanoDoce® in Participants With Urothelial Carcinoma
NanOlogy, LLC
Phase 1/2 Completed
NCT02449239 2023-07-24
VISTA
Sesen Bio, Inc.
Phase 3 Completed
NCT03191578 2023-07-14
RUTIVAC-1
Archivel Farma S.L.
Phase 1 Completed
NCT03854721 2023-03-03
A Phase 1 Study of Intravesical VAX014 for Instillation in Subjects With Non-Muscle Invasive Bladder Cancer
Vaxiion Therapeutics
Phase 1 Completed
NCT03664258 2023-02-13
ANTICIPATE X
Cepheid
Completed
NCT03558503 2022-09-16
OPTIMA II
UroGen Pharma Ltd.
Phase 2 Completed
NCT02316171 2022-07-27
CANON
Viralytics
Phase 1 Completed
NCT00318643 2021-10-29
Safety Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Participants With Superficial Bladder Cancer
Halozyme Therapeutics
Phase 1/2 Completed
NCT02009332 2021-06-08
Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
Aadi Bioscience, Inc.
Phase 1/2 Completed
NCT02969109 2021-03-02
Validation of a Urine-based Assay With Genomic Markers for Predicting Recurrence for Non-muscle Invasive Bladder Cancer
Genomic Health®, Inc.
Completed
NCT04498702 2020-08-13
Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG Therapy
Jiangsu Yahong Meditech Co., Ltd aka Asieris
Phase 2 Completed
NCT00595088 2019-04-30
Phase 2b, Trial of Intravesical DTA-H19/PEI in Patients With Intermediate-Risk Superficial Bladder Cancer
Anchiano Therapeutics Israel Ltd.
Phase 2 Completed
NCT03053635 2018-08-20
Intravesical Photodynamic Therapy (PDT) in BCG Refractory High-Risk Non-muscle Invasive Bladder Cancer (NMIBC) Patients
Theralase® Technologies Inc.
Phase 1 Completed
NCT02560584 2018-07-02
A Study of Blue Light Flexible Cystoscopy With Cysview in the Detection of Bladder Cancer in the Surveillance Setting
Photocure
Phase 3 Completed
NCT01687244 2017-07-24
Intravesical Administration of rAd-IFN/Syn3 in Patients With BCG-Refractory or Relapsed Bladder Cancer
FKD Therapies Oy
Phase 2 Completed
NCT01803295 2017-06-16
OPTIMA
UroGen Pharma Ltd.
Phase NA Completed
NCT02307487 2017-06-16
Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients
UroGen Pharma Ltd.
Phase 2 Completed
NCT02891460 2016-09-08
Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients
UroGen Pharma Ltd.
Phase NA Completed
NCT02007005 2015-05-06
Maximum Tolerable Concentration of abnobaVISCUM Fraxini Intravesically in Patients With Superficial Bladder Cancer
Abnoba Gmbh
Phase 1/2 Completed
NCT01731652 2015-02-10
Study With TMX-101 in Patients With Carcinoma In Situ (CIS) Bladder Cancer
Telormedix SA
Phase 2 Completed
NCT01304173 2014-02-19
Retrospective Chart Review of Valstar
Endo Pharmaceuticals
Completed
NCT01648010 2013-05-07
Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel Device In Patients With Muscle Invasive Bladder Cancer
UroGen Pharma Ltd.
Phase NA Completed
NCT01458847 2012-11-12
Cis-urocanic Acid (Cis-UCA) in Patients With Primary or Recurrent Non-muscle Invasive Bladder Cancer
BioCis Pharma Ltd
Phase 1 Completed
NCT00782587 2010-02-08
IPOP
Halozyme Therapeutics
Phase 1 Completed
NCT00192049 2007-05-17
A Randomized Study Comparing Single Agent Gemcitabine Intravesical Therapy Versus Mitomycin C in Patients With Intermediate Risk Superficial Bladder Cancer
Eli Lilly and Company
Phase 2 Completed
NCT00191711 2007-01-26
Intravesical Gemcitabine Instillation Followed by Transurethral Resection for the Treatment of Patients With Superficial Bladder Cancer at Low Risk.
Eli Lilly and Company
Phase 2 Completed